09:41 AM EST - Oncolytics Biotech Inc. : Provided a letter to shareholders. Dr. Matt Coffey, President & CEO stated, the AWARE-1 study results presented this past year exceeded our expectations and provided us with additional confidence in our overall clinical development program. We are well on our way to completing enrollment in BRACELET-1, expected to occur in early 2022. The combination of clinical data from BRACELET-1 along with data from AWARE-1 will provide the final elements necessary to develop and launch a registrational study in metastatic breast cancer. Oncolytics Biotech Inc.
shares T.ONC are trading unchanged at $1.70.
